AKT1 and neoplasm: SLIT2 has been shown to inhibit EMT in CRC through the protein kinase B-glycogen synthase kinase 3 β (AKT-GSK3β) signaling pathway [55]; therefore, the hypermethylation of SLIT2 promoter reverses the inhibition of EMT, facilitating tumor progression.